NCT06087757View on ClinicalTrials.gov

Clemastine Treatment in Individuals With Williams Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Williams Syndrome
Interventions
DRUG

Open Label Clemastine with a blinded randomize withdrawal

Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.

Trial Locations (2)

Unknown

RECRUITING

Child and Adolescent Psychiatry Unit, Sheba Medical Center, Ramat Gan

RECRUITING

Tel Aviv University, Tel Aviv

All Listed Sponsors
collaborator

Tel Aviv University

OTHER

lead

Sheba Medical Center

OTHER_GOV